-
SeeNeuro Medical Raises RMB 100M in Series B Funding for Neural Regulation Devices
•
Hangzhou-based SeeNeuro Medical, a developer of implantable neural regulation devices, has reportedly raised RMB 100 million (USD 13.7 million) in a Series B financing round. The funding was led by SDIC Unity Capital, with participation from BioTrack Capital, a returning investor. The proceeds will be used to support new product…
-
Rici Healthcare to Acquire Unicorn II Holdings for RMB 180M
•
China-based Rici Healthcare Holdings Limited (HKG: 1526), also known as Rich Healthcare, is set to acquire 1,672,140 shares of Unicorn II Holdings Limited for RMB 180 million (USD 24.7 million). The acquisition aims to strengthen Rici Healthcare’s position in the rapidly growing private medical services sector in China. Market Growth…
-
Kactus Biosystems Raises RMB 200M in Series B Financing for Protein and Enzyme Development
•
Kactus Biosystems, a Shanghai-based firm specializing in target proteins and raw enzymes, has raised RMB 200 million (USD 27.6 million) in a Series B financing round. The round was led by New Alliance Capital, with participation from Lingang Group’s healthcare industry fund, GF Capital, and a “famous multinational life science…
-
Sichuan Biokin Pharma Plans IPO on STAR Board to Raise RMB 1.422 Billion
•
China-based Sichuan Biokin Pharmaceutical Co., Ltd is set to conduct an initial public offering (IPO) of 40.1 million shares on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). The offering is expected to raise a total of RMB 1.422 billion (USD 196.6 million). The proceeds will be allocated towards the…
-
Shanghai’s Hrain Biotechnology Plans IPO on STAR Board to Raise RMB 2.539 Billion
•
Shanghai-based Hrain Biotechnology Co., Ltd, a specialist in tumor immunotherapy, plans to conduct an initial public offering (IPO) of 50 million shares on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). The offering is expected to raise RMB 2.539 billion (USD 352.6 million). The proceeds will be allocated towards cell…
-
Shenzhen GeneBioHealth Secures USD 15M for Bio-Business Expansion
•
Shenzhen GeneBioHealth Co., Ltd, a China-based in-vitro diagnostic (IVD) medical device developer, has reportedly raised USD 15 million in a Series B+ financing round. The funds will be used to support bio-business development and product pipeline research and development (R&D). This investment underscores the company’s commitment to advancing its diagnostic…
-
PureID Medical Technology Secures RMB 100M Series B Funding
•
PureID Medical Technology Co., Ltd, a medical device compliance service provider based in Guangzhou, has reportedly raised over RMB 100 million (USD 13.89 million) in a Series B financing round. The round was led by Legend Capital, with a contribution from existing investor Bayland Capital. The proceeds will be used…
-
Salus Biomed Raises Over RMB 100M in Pre-Series A Financing
•
Salus Biomed, a sequencing and spatial omics platform provider based in Guangdong, has reportedly raised over RMB 100 million (USD 13.89 million) in a Pre-Series A financing round. The funding will support regulatory filings and ongoing research and development of its gene sequencing platform and super-resolution spatial omics products, as…
-
Kunshi Biotechnology Raises Angel Funding for Engineered Macrophage Platform
•
China-based Kunshi Biotechnology (Shenzhen) Co., Ltd, a company specializing in gene editing, biomaterials, and synthetic biology-driven platforms for engineered macrophages to treat solid tumors, has reportedly raised “tens of millions” of renminbi in an angel financing round. The funding was led by ASB Ventures, Riemann Hypothesis, and other investors. The…
-
Sihuan Pharma to Acquire Additional Stake in Heilongjiang Duoduo Pharma
•
China-based Sihuan Pharmaceutical Holdings Group Ltd’s subsidiary, Beijing Centergate Technologies (Holding) Co., Ltd (SHE: 000931), has announced that Sihuan Pharma is set to acquire an additional 9.56% stake in Heilongjiang Duoduo Pharmaceutical Co., Ltd. Upon the deal’s closure, Sihuan will own a 78.82% stake in Duoduo Pharma, maintaining its position…
-
Ningbo Menovo to Sell Zhejiang Liaoyuan Pharma Stake to Jemincare for RMB 512.58M
•
China-based Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538) has announced plans to transfer all of its ownership in Zhejiang Liaoyuan Pharmaceutical Co., Ltd (23,771,218 shares, or 84.5661% of the target company’s total shares) to Jiangxi Jemincare Group for a consideration of RMB 512.58 million (USD 71.2 million). The deal is…
-
Alioth Biotech Raises RMB 100M in Series A Financing for Pharma Processing Products
•
China-based Alioth Biotech (Shanghai) Co., Ltd has raised close to RMB 100 million (USD 13.9 million) in a Series A financing round. The round was led by Matrix Partners and Legend Capital, with participation from Shanghai Yishuishan Enterprise Consulting Partnership Limited. The proceeds will be used to construct a membrane…
-
HICOMP MicroTech Raises RMB 100M in Series B+ Financing for Microfluidics Expansion
•
China-based micro/nano technology developer HICOMP MicroTech (Suzhou) Co., Ltd has raised RMB 100 million (USD 13.9 million) in a Series B+ financing round. The round was led by Shunwei Capital, with contributions from IC Space’s industrial investment platform. The proceeds will be used to support microfluidics research and development (R&D),…
-
AlphaLife Sciences Raises Series A+ Funding for Clinical Research SaaS
•
China-based clinical research SaaS service provider AlphaLife Sciences has reportedly raised “tens of millions” of US dollars in a Series A+ financing round. The round was led by Hankang Capital, with participation from B Capital. The proceeds will be used to further develop and expand the company’s next-generation clinical study…
-
SprintRay Raises Over USD 100M in Series D Financing for Dental 3D Printing
•
Zhejiang-based SprintRay Co., a one-stop digital chair side solution provider for dental institutions, has reportedly raised over USD 100 million in a Series D financing round. The round was led by SoftBank Vision Fund 2, with contributions from Yiheng Capital and ZWC Partners, alongside existing investors CDBI Partners and Marathon…
-
VectorBuilder Raises $56.6M in Series C to Expand Life Science R&D
•
Guangzhou-based VectorBuilder, a genetic engineering specialist incubated by the state-owned Guangzhou Industrial Investment and Capital Operation Holding Group, has reportedly raised RMB 410 million ($56.6 million) in a Series C financing round. The funding round saw participation from investors including Guangzhou Industrial Investment and Capital Operation, Legend Capital, Yuexiu Industry…
-
Roche Boosts China Investment with Additional RMB 250 Million
•
Swiss pharmaceutical giant Roche (SWX: ROG) has pledged to invest an additional RMB 250 million (USD 35.1 million) in China, underscoring its commitment to the market despite challenges posed by the COVID-19 pandemic. The announcement was made during the 34th International Business Leaders’ Advisory Council for the Mayor of Shanghai.…
-
Betta Pharmaceuticals Raises $140.5M for Drug Industrialization Base in Zhejiang
•
China’s Betta Pharmaceuticals Co., Ltd. (SHE: 300558) plans to raise RMB 1 billion ($140.5 million) through a private placement of 25,967,281 shares at RMB 38.51 ($5.41) per share. The shares will be issued to Ding Lieming, the company’s legal controller. The proceeds will be used to construct a novel drug…
-
NeuShen Therapeutics Closes $20M Series Pre-A Financing for CNS Drug Development
•
NeuShen Therapeutics has announced the successful closure of a $20 million Series pre-A financing round led by Lapam Capital. The proceeds will be used to advance the company’s central nervous system (CNS) drug research and development platform, as well as to support the development of new drugs targeting CNS disorders.…
